| Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 22968891 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Considerable controversy exists regarding the association of omega-3 polyunsaturated fatty acids (PUFAs) and major cardiovascular end points. OBJECTIVE: To assess the role of omega-3 supplementation on major cardiovascular outcomes. DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials through August 2012. STUDY SELECTION: Randomized clinical trials evaluating the effect of omega-3 on all-cause mortality, cardiac death, sudden death, myocardial infarction, and stroke. DATA EXTRACTION: Descriptive and quantitative information was extracted; absolute and relative risk (RR) estimates were synthesized under a random-effects model. Heterogeneity was assessed using the Q statistic and I2. Subgroup analyses were performed for the presence of blinding, the prevention settings, and patients with implantable cardioverter-defibrillators, and meta-regression analyses were performed for the omega-3 dose. A statistical significance threshold of .0063 was assumed after adjustment for multiple comparisons. DATA SYNTHESIS: Of the 3635 citations retrieved, 20 studies of 68,680 patients were included, reporting 7044 deaths, 3993 cardiac deaths, 1150 sudden deaths, 1837 myocardial infarctions, and 1490 strokes. No statistically significant association was observed with all-cause mortality (RR, 0.96; 95% CI, 0.91 to 1.02; risk reduction [RD] -0.004, 95% CI, -0.01 to 0.02), cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; RD, -0.01; 95% CI, -0.02 to 0.00), sudden death (RR, 0.87; 95% CI, 0.75 to 1.01; RD, -0.003; 95% CI, -0.012 to 0.006), myocardial infarction (RR, 0.89; 95% CI, 0.76 to 1.04; RD, -0.002; 95% CI, -0.007 to 0.002), and stroke (RR, 1.05; 95% CI, 0.93 to 1.18; RD, 0.001; 95% CI, -0.002 to 0.004) when all supplement studies were considered. CONCLUSION: Overall, omega-3 PUFA supplementation was not associated with a lower risk of all-cause mortality, cardiac death, sudden death, myocardial infarction, or stroke based on relative and absolute measures of association. |
| | |
Authors:
|
Evangelos C Rizos; Evangelia E Ntzani; Eftychia Bika; Michael S Kostapanos; Moses S Elisaf |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Review |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 308 ISSN: 1538-3598 ISO Abbreviation: JAMA Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-09-12 Completed Date: 2012-09-14 Revised Date: 2013-01-29 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: United States |
Other Details:
|
Languages: eng Pagination: 1024-33 Citation Subset: AIM; IM |
Affiliation:
|
Lipid Disorders Clinic, Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Cardiovascular Diseases / mortality*, prevention & control* Cause of Death Death, Sudden, Cardiac / epidemiology Dietary Supplements* Fatty Acids, Omega-3 / therapeutic use* Humans Middle Aged Myocardial Infarction / mortality, prevention & control Randomized Controlled Trials as Topic Risk Stroke / mortality, prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids, Omega-3 |
| Comments/Corrections | |
Comment In:
|
JAMA. 2013 Jan 2;309(1):28
[PMID:
23280210
]
Ann Intern Med. 2012 Dec 18;157(12):JC6-5 [PMID: 23247954 ] JAMA. 2013 Jan 2;309(1):29 [PMID: 23280212 ] JAMA. 2013 Jan 2;309(1):27-8 [PMID: 23280209 ] JAMA. 2013 Jan 2;309(1):28-9 [PMID: 23280211 ] JAMA. 2013 Jan 2;309(1):27 [PMID: 23280208 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Spending differences associated with the Medicare Physician Group Practice Demonstration.
Next Document: The surgical safety checklist survey: a national perspective on patient safety.